Athira Pharma, Inc.

NasdaqGS:ATHA 株式レポート

時価総額：US$23.3m

Athira Pharma マネジメント

マネジメント 基準チェック /14

Athira Pharmaの CEO はMark Littonで、 Oct2021年に任命され、 の在任期間は 3.08年です。 の年間総報酬は$ 2.26Mで、 25.9%給与と74.1%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.47%を直接所有しており、その価値は$ 108.49K 。経営陣と取締役会の平均在任期間はそれぞれ1.8年と3年です。

主要情報

Mark Litton

最高経営責任者

US$2.3m

報酬総額

CEO給与比率25.9%
CEO在任期間3.1yrs
CEOの所有権0.5%
経営陣の平均在職期間1.8yrs
取締役会の平均在任期間3yrs

経営陣の近況

Recent updates

Will Athira Pharma (NASDAQ:ATHA) Spend Its Cash Wisely?

Feb 16
Will Athira Pharma (NASDAQ:ATHA) Spend Its Cash Wisely?

Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Invest In Growth?

Nov 02
Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Invest In Growth?

Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Invest In Growth?

May 29
Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Invest In Growth?

Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Deliver On Growth Plans?

Jan 04
Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Deliver On Growth Plans?

Athira Alzheimer's drug trial gets monitoring panel nod to continue after efficacy analysis

Oct 17

Athira Pharma GAAP EPS of -$0.65

Aug 15

We're Hopeful That Athira Pharma (NASDAQ:ATHA) Will Use Its Cash Wisely

Aug 09
We're Hopeful That Athira Pharma (NASDAQ:ATHA) Will Use Its Cash Wisely

Athira Pharma: The Market Is Missing A Potential New Alzheimer's Drug

Jun 22

Companies Like Athira Pharma (NASDAQ:ATHA) Are In A Position To Invest In Growth

May 08
Companies Like Athira Pharma (NASDAQ:ATHA) Are In A Position To Invest In Growth

We're Not Very Worried About Athira Pharma's (NASDAQ:ATHA) Cash Burn Rate

Jan 11
We're Not Very Worried About Athira Pharma's (NASDAQ:ATHA) Cash Burn Rate

Athira Pharma: What, Exactly, Did The CEO Do?

Jun 29

Athira Pharma falls after the decision to place CEO on temporary leave

Jun 17

Athira surges after Jefferies estimated 50% gain on FDA approval for Biogen’s Alzheimer’s therapy

Jun 07

We Think Athira Pharma (NASDAQ:ATHA) Can Afford To Drive Business Growth

May 24
We Think Athira Pharma (NASDAQ:ATHA) Can Afford To Drive Business Growth

We're Hopeful That Athira Pharma (NASDAQ:ATHA) Will Use Its Cash Wisely

Feb 08
We're Hopeful That Athira Pharma (NASDAQ:ATHA) Will Use Its Cash Wisely

Athira: Early Stage Alzheimer's Therapeutics With An Interesting Approach

Jan 11

Here's What Athira Pharma, Inc.'s (NASDAQ:ATHA) Shareholder Ownership Structure Looks Like

Dec 18
Here's What Athira Pharma, Inc.'s (NASDAQ:ATHA) Shareholder Ownership Structure Looks Like

Athira Pharma nabs research grant of $15M from NIH

Dec 08

Athira Pharma reports Q3 results

Nov 12

CEO報酬分析

Athira Pharma の収益と比較して、Mark Litton の報酬はどのように変化したか？
日付総報酬給与会社業績
Jun 30 2024n/an/a

-US$113m

Mar 31 2024n/an/a

-US$116m

Dec 31 2023US$2mUS$585k

-US$118m

Sep 30 2023n/an/a

-US$121m

Jun 30 2023n/an/a

-US$108m

Mar 31 2023n/an/a

-US$102m

Dec 31 2022US$4mUS$543k

-US$96m

Sep 30 2022n/an/a

-US$82m

Jun 30 2022n/an/a

-US$77m

Mar 31 2022n/an/a

-US$67m

Dec 31 2021US$3mUS$450k

-US$55m

Sep 30 2021n/an/a

-US$46m

Jun 30 2021n/an/a

-US$39m

Mar 31 2021n/an/a

-US$27m

Dec 31 2020n/an/a

-US$20m

Sep 30 2020n/an/a

-US$13m

Jun 30 2020n/an/a

-US$6m

Mar 31 2020n/an/a

-US$6m

Dec 31 2019US$204kUS$12k

-US$5m

報酬と市場: Markの 総報酬 ($USD 2.26M ) は、 US市場 ($USD 653.78K ) の同規模の企業の平均を上回っています。

報酬と収益: Markの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Mark Litton (56 yo)

3.1yrs

在職期間

US$2,261,564

報酬

Dr. Mark J. Litton, Ph D., MBA, serves as Director at Lumen Bioscience, Inc. since October 2020. He served as Chief Operating Officer of Athira Pharma, Inc. since July 2019 until October 18, 2021 and serve...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Mark Litton
President3.1yrsUS$2.26m0.47%
$ 108.5k
Robert Renninger
VP of Financeless than a yearデータなし0.20%
$ 46.4k
Kevin Church
Chief Scientific Officer1.8yrsUS$135.32k0.24%
$ 56.2k
Julie Rathbun
Head of Investor Relationsno dataデータなしデータなし
Mark Worthington
General Counsel3.4yrsUS$2.71m0.14%
$ 31.5k
Javier San Martin
Chief Medical Officerless than a yearデータなしデータなし

1.8yrs

平均在職期間

56yo

平均年齢

経験豊富な経営陣: ATHAの経営陣は 経験豊富 とはみなされません ( 1.8年の平均在職年数)。これは新しいチームを示唆しています。

取締役

名称ポジション在職期間報酬所有権
Mark Litton
President3.1yrsUS$2.26m0.47%
$ 108.5k
John Fluke
Independent Director9.9yrsUS$95.89k0.38%
$ 87.8k
Grant Pickering
Independent Director2.8yrsUS$96.53k0.067%
$ 15.6k
Kelly Romano
Independent Chairwoman of the Board3.9yrsUS$124.68k0.21%
$ 48.9k
Joseph Edelman
Independent Director4.5yrsUS$92.77k0%
$ 0
Hans Moebius
Member of Scientific Advisory Board2.4yrsUS$1.29m0.24%
$ 55.4k
Marwan Sabbagh
Member of Scientific Advisory Board2.4yrsデータなしデータなし
Barbara Kosacz
Independent Director3.7yrsUS$102.39k0%
$ 0
Michael A. Panzara
Independent Director2.7yrsUS$89.36k0%
$ 0
James Johnson
Independent Director4.3yrsUS$106.87k0.013%
$ 3.0k
John Olichney
Member of Scientific Advisory Board2.4yrsデータなしデータなし
Anton Porsteinsson
Member of Scientific Advisory Board2.4yrsデータなしデータなし

3.0yrs

平均在職期間

64yo

平均年齢

経験豊富なボード: ATHAの 取締役会 は 経験豊富 ではない ( 3年の平均在任期間) ため、新しい取締役会が必要であると考えられます。